recording

POSTERS ESMO 2024

esmo

Cáncer de mama

Cáncer de mama temprano

Isabel Echavarria Díaz-Guardamino

acceso

Subtyping of residual disease (RD) following neoadjuvant chemotherapy (NACT) for triple negative breast cancer (TNBC): evolution and prognostic impact

  • Isabel Echavarria Díaz-Guardamino

    Hospital General Universitario Gregorio Marañón. Madrid
Marta Tapia Céspedes

acceso

Personalized treatment approaches with HER2DX in early HER2-positive breast cancer: a precision tool for treatment decision-making.

  • Marta Tapia Céspedes

    Hospital Clínico Universitario de Valencia

Cáncer de mama

Cáncer de mama metastásico

Mafalda Oliveira

acceso

Interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC).

  • Mafalda Oliveira

    Hospital Universitario Vall d’Hebron. Barcelona
Sara Cabrero-de las Heras

acceso

Identification of circulating immune factors as predictive biomarkers of CDK4/6i treatment efficacy in advanced breast cancer.

  • Sara Cabrero-de las Heras

    Investigadora Postdoctoral en Cáncer de mama IrsiCaixa

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON